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Abstract
Fibroblast growth factor 23 (FGF23) is a circulating hormone important in phosphate homeostasis. Abnormal serum levels
of FGF23 result in systemic pathologies in humans and mice, including renal phosphate wasting diseases and
hyperphosphatemia. We sought to uncover the role FGF23 plays in the auditory system due to shared molecular
mechanisms and genetic pathways between ear and kidney development, the critical roles multiple FGFs play in auditory
development and the known hearing phenotype in mice deficient in klotho (KL), a critical co-factor for FGF23 signaling.
Using functional assessments of hearing, we demonstrate that Fgf23z={ mice are profoundly deaf. Fgf23z={ mice have
moderate hearing loss above 20 kHz, consistent with mixed conductive and sensorineural pathology of both middle and
inner ear origin. Histology and high-voltage X-ray computed tomography of Fgf23{={ mice demonstrate dysplastic bulla
and ossicles; Fgf23z={ mice have near-normal morphology. The cochleae of mutant mice appear nearly normal on gross
and microscopic inspection. In wild type mice, FGF23 is ubiquitously expressed throughout the cochlea. Measurements
from Fgf23{={ mice do not match the auditory phenotype of Kl
2/2 mice, suggesting that loss of FGF23 activity impacts the
auditory system via mechanisms at least partially independent of KL. Given the extensive middle ear malformations and the
overlap of initiation of FGF23 activity and Eustachian tube development, this work suggests a possible role for FGF23 in
otitis media.
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Introduction
Fibroblast growth factor 23 (FGF23) is a circulating hormone,
typically secreted by osteoblasts and osteocytes, which regulates
renal phosphate handling [1,2,3]. Phosphate wasting diseases
(including tumor-induced osteomalacia, X-linked and autosomal-
dominant hypophosphatemic rickets, all of which may present
with hearing phenotypes) occur with elevated serum levels of
FGF23 [4,5,6]. Reduced FGF23 activity leads to decreased
urinary excretion of phosphate [7], as in familial tumoral
calcinosis. Mice deficient in Fgf23 exhibit severe hyperphospha-
temia, hypervitaminosis D, hypercalcemia, ectopic calcifications,
growth retardation, organ atrophy, infertility and shortened life
expectancy [8,9,10,2].
This study sought to characterize the murine auditory
phenotype due to FGF23 deficiency because other members of
the FGF superfamily are critical for normal development of the
auditory system in humans and animal models [11,12,13,14],
kidney and inner ear development rely on shared molecular
mechanisms and genetic pathways [15,16] and both organs are
susceptible to toxicity from aminoglycoside antibiotics and loop
diuretics [16,17,18]. Additionally, deficiency in klotho (KL), a
critical co-factor for FGF23 mediated signaling [19,20], results in
hearing loss [21,22]. Alpha-KL is a single-pass transmembrane
protein that increases FGF receptor (FGFR) affinity for FGF23
[19,20] and decreases affinity to other FGFs. KL expression has
been reported in several cochlear cell types [22,23], but the
sensory epithelia of Kl
2/2 mice appear normal [21]. The skeletal
phenotypes present in Fgf23{={ mice are also present in Kl
2/2
mice and double knockouts. Bioactive FGF23 injection results in
phenotypic rescue of Fgf23{={ mice but not in KL knockouts
[24]. A vitamin D-deficient diet rescues the auditory and systemic
Kl
2/2 phenotypes [21,25]. Injection of just the C-terminal tail of
FGF23, capable of binding the FGFR1c-Klotho complex but not
regulating phosphate handling, can reduce phosphate wasting via
receptor competition in both normal and FGF23 over-expresser
mice [26].
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107681It is currently unclear if the Kl
2/2 auditory phenotype is due to
altered FGF23 signaling because KL and FGF23 can exhibit
functions independent of each other [27,28]. However, the leading
hypothesis is that hearing loss results from demineralization of the
auditory ossicles, resulting from hypervitaminosis D [21] induced
by loss of renal FGF23 activity. If correct, hearing loss should be
seen in Fgf23{={ mice and should be conductive in nature. To
understand the relevance of FGF23 in auditory function, we
studied Fgf23{={ and Fgf23z={ mice using physiologic,
histologic and radiologic tools. We demonstrate that FGF23 is
critical for normal development of the middle ear and for function
of both the middle and inner ear. We also demonstrate a
connection between FGF23 deficiency and predilection to otitis
media. This finding has diagnostic and therapeutic implications as
the genetic basis of human otitis media is poorly understood [29]
and otitis media is the most common cause for pediatric antibiotic
and surgical intervention [30].
Materials and Methods
For this study, we utilized a previously developed Fgf23 null
mouse (Fgf23{={) [2,24,31] in which the entire Fgf23 gene has
been replaced with the lacZ gene. Male, 6-week old mice were
generated via the breeding of Fgf23z={ mice. Genotypes were
confirmed with PCR. All studies were approved by the Institu-
tional Animal Care and Use Committee at Harvard Medical
School.
Audiometric testing
Physiologic performance of the auditory systems of Fgf23{={,
Fgf23z={, and Fgf23z=z littermates was assessed using auditory
brainstem response (ABR), which assess organ and neural
function, and distortion product oto-acoustic emission (DPOAE)
measurements, which assess middle ear function and cochlear
amplification. ABR waveforms were recorded from anesthetized
mice (ketamine 0.1 mg/g and xylazine 0.02 mg/g) via sub-dermal
electrodes placed at the ipsilateral pinna and vertex (grounded at
the junction of the tail and torso). A brief tone was presented into
the ipsilateral ear canal and the resulting electrode waveform was
recorded and averaged (512 presentations, presented at 40 Hz).
Tones were presented at frequencies from 5.66–45.25 kHz in half-
octave steps and intensities ranging 15–80 dB SPL in 5 dB steps.
Threshold was defined as the first intensity at which recognizable
and repeatable peaks became observable in the averaged
recording. ABR wave I amplitude (measured peak-to-peak from
the local maxima of PI to the local minima of NI) and latency
were determined for each frequency and intensity using the ABR
Peak Analysis software (Bradley Buran, Eaton-Peabody Labora-
tory). Amplitude and latency values were calculated for the middle
5 frequency points due to increased noise in the highest and lowest
measurements. Latency values are presented in dB SL (sensation
level), as opposed to dB SPL like amplitude measurements. At high
enough stimulation intensities (§60 dB SPL tones) ABR
amplitudes have a greater dependance on absolute intensity due
to growth of excitation and cochlear saturation.
DPOAEs were measured in anesthetized mice via simultaneous
presentation of two tones (denoted f1 and f2, the frequency of
f2~1:2f1 Hz and intensity of f2~f1{10 dB SPL) into the
ipsilateral ear canal while concurrently recording ear canal sound
pressure. The energy of the 2f1{f2 Hz distortion tone, generated
by non-linear cochlear amplification of the input tones, was
monitored and threshold defined as the f2 tone intensity which
generates a distortion tone greater than 0 dB SPL (noise floor
*{10 dB SPL).
Differences between mutant and wildtype threshold, magnitude
and latency values were tested for statistical significance using
Welch’s t test. ABR threshold, amplitude and latency data are
from N=7, 3 and 3 animals from the Fgf23{={, Fgf23z={, and
Fgf23z=z genotypes respectively. DPOAE thresholds were
measured from N=5, 4 and 9 ears of each genotype.
Histology and Immunohistochemistry
Histologic sections were prepared to assess the microscopic
anatomy of the inner ear. Mice were anesthetized using ketamine
(0.1 mg/g) and xylazine (0.02 mg/g) before intra-cardiac perfu-
sion. 4% paraformaldehyde (PFA) was used for paraffin embed-
ding and 1.5% PFA/2.5% gluteraldehyde for araldite work. A
ventral approach was performed to expose the bulla and tympanic
membrane for photography and extraction. The round and oval
windows were perforated and intra-cochlear perfusion was
performed to improve tissue preservation. Cochleae were extract-
ed and submerged in fixative for 2 hours at room temperature.
Samples for paraffin embedding were decalcified in EDTA for 2
days and stained with hematoxylin and eosin. Cochleae for
araldite embedding were incubated in 1% osmium tetroxide for
1 hour and decalcified in EDTA with 1% gluteraldehyde for 3–4
days at room temperature.
Slides for FGF23 immunostaining were deparaffinized in xylene
and rehydrated with an alcohol ladder (100%, 95%, 75% and
50%). Sections were immersed in 3% H2O2 in methanol, then
blocked in 5% goat serum for 30 minutes, and incubated with rat
anti-FGF23 primary antibody (AMGEN, 1:200) overnight at 4uC.
Biotinylated goat anti-rat secondary antibody (Vector Laborato-
ries, BA-9401, 1:200) was applied for 1 hour at room temperature
followed by HRP substrate (BD Pharmingen, 92121) and
developed with DAB for 2 minutes (Vector Laboratories,
SK4100, 1:10). Slides were counterstained with hematoxylin
(VWR, 95057-844).
mCT analysis
Gross morphology of the bulla, ossicles and cochlea of
Fgf23{={ and Fgf23z=z mice were studied using high-voltage
X-ray computed tomography (mCT). Mice were anesthetized and
intra-cardially fixed as above. Soft tissues were removed from the
head to expose the skull. The cranium and hard palate were
carefully dissected, leaving only the portion of the skull base
between the bullae and extending forward to contain the bony ear-
canals. The tympanic membrane of each ear was perforated and
samples were fixed overnight in 4% PFA.
mCT scans were performed on a Scanco Medical mCT35
System (Scanco Medical, Bru ¨ttlsellen, Switzerland). Scans were
conducted in 70% ethanol with parameters: voxel size - 7 mm, X-
ray tube potential - 55 kVp, X-ray intensity - 0.145 mA and
integration time - 600 ms (as detailed in [31]).
Raw mCT data were imported into Voxar 3D 6.3 (Toshiba
Medical Visualization Systems, Japan). For the 2D reformats, the
raw data for each ear were separated and then brought up on a
clinical imaging work station viewing console, where the raw data
were displayed in three orthogonal planes. The data were first
reformatted into a dataset of 7 mm thick images rendered in a
plane parallel to the posterior semicircular canal (PSCC) and
sagittal to the head. An orthogonal coronal data set was then made
in a plane perpendicular to the PSCC and coronal to the head.
For the 3D reconstructions, the raw data for each ear were
displayed using 3D volume rendering with preset window level
FGF23 Deficiency and Hearing Loss
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provided by the software developer). Regions of interest were
manually segmented to exclude the walls of the middle ear and to
isolate the ossicles.
The sagittal and coronal images, and segmented 3D recon-
structions from the Fgf23{={ samples were reviewed and
compared with the Fgf23z=z specimens with regard to morphol-
ogy of the ossicles, contour of the incudomalleal joint, pneuma-
tization of the petrous apex, pneumatization of the mastoid,
Eustachian tube patency and CT homogeneity of the bulla, otic
capsule and ossicles.
Results
Anatomic Findings
Morphological assessments of middle and inner ear anatomy
revealed that bullae from Fgf23{={ mice appear cloudy and lack
the precise refinement in shape that is characteristic in Fgf23z=z
mice (Fig. 1A). The auditory ossicles are similarly a cloudy white
hue and show significant dysplasia, consistent with abnormal bone
remodeling (Fig. 1B). In contrast, the cochleae and vestibular
organs of all genotypes appear similar, although Fgf23{={
cochleae are slightly smaller and whiter (Fig. 2). The bullae of
Fgf23z={ mice have normal shape but small, white, cloudy
patches. The ossicles appear slightly dysplastic. In no cases did the
Fgf23z={ morphological phenotype approach the severity of the
Fgf23{={ mice. Middle ear effusions and signs of otitis media
were observed in 4 of 5 Fgf23{={ and 1 of 3 Fgf23z={ mice.
Our finding of severe middle-ear phenotypes in Fgf23{={ mice
are consistent with the phenotype described in other bones,
including severe axial and appendicular skeletal malformations,
characterized by nodules, rachitic lesions and narrowed growth
plates [2]. Others have not observed obvious abnormality in the
Fgf23z={ genotype [9].
The membranous labyrinth of the inner ear appears anatom-
ically normal, healthy and properly organized in Fgf23{={ mice
(Fig. 3). However, inspection of the bony labyrinth in Fgf23{={
mice uncovers phenotypic differences. The modiolus appears to
have increased vascularization (Fig. 1C, arrowheads) and the
highly organized laminar sheets of the otic capsule are replaced by
swirling structures in the region bordering the spiral ligament
(Fig. 1D).
Immunostaining of cochlear slides revealed the widespread
presence of FGF23 throughout most cell types of the inner ear
(Fig. 4). Immunoreactivity was observed within cells of the spiral
ligament, stria vascularis, Organ of Corti, spiral limbus and within
the spiral ganglion neuronal cell bodies as well as osteocytes in
Fgf23z=z (Fig. 4A) and Fgf23z={ mice (not shown). The
strongest staining was observed in the stria vascularis and Organ
of Corti. No Immunoreactivity was observed in Fgf23{={ mice
(Fig. 4B), or in Fgf23z=z mice processed without the primary
antibody (Fig. 4C), indicating the antibodies are reacting specif-
ically.
mCT Reconstruction
Comparison of 2D mCT sections from Fgf23{={ and
Fgf23z=z mice (N=2,2) uncovered several bony phenotypes of
the ossicles and mastoid bone. The malleal head appears dysplastic
in Fgf23{={ specimens (Fig. 5C), as does the incus, either
abnormally notched or heart-shaped, and the stapes demonstrates
thickening of the crua and footplate (Fig. 5B). The incudomalleal
joint appears abnormally contoured in the Fgf23{={ genotype,
rough, irregular and notched, compared to the smoothly
contoured, tight fitting and angular interface of the Fgf23z=z
mice (Fig. 5C). The mastoid (Fig. 5C) and petrous apex (Fig. 5B)
are substantially under-pneumatized. The bony portion of the
Eustachian tube is patent and similar to Fgf23z=z mice (Fig. 5C).
The incus and malleal head appear heterogeneously lucent when
compared to the homogeneously dense formations found in the
Fgf23z=z mice (Fig. 5C). Similarly, the bulla, otic capsule and
vestibular compartments are characterized by lower density and
poor lamellar organization (Fig. 5A).
Three-dimensional reconstruction of the ossicles highlights the
lack of structural refinement in Fgf23{={ mice (Fig. 5D). Regions
with particularly noticeable dysplasias include the incudal pocket,
manubrium and separation of the malleal ridge and head. The
lucency of the Fgf23{={ bones, versus the diffusely dense
Fgf23z=z counterparts (noted above), is reflected in the unsharp-
ness of the borders of both 3D reconstructed Fgf23{={ ossicular
chains. This results from poor mCT contrast with surroundings
due to lower ossicular density.
Audiometric Assessment
ABR measurements (Fig. 6A) demonstrate that Fgf23{={ mice
have profound hearing loss across all frequencies compared to
Fgf23z=z littermates (pƒ0:001). Fgf23z={ mice have normal
hearing below 20 kHz and losses of up to 25 dB above that
frequency. DPOAE measurements demonstrate similar trends
(Fig. 6B): Fgf23{={ mice have nearly complete hearing loss while
Fgf23z={ mice demonstrate 40 dB of loss at the highest
frequencies and have normal hearing below 30 kHz.
Because ABR threshold measurements are known to be
insensitive to certain types of neural damage [32], ABR wave I
amplitude and latency were also analyzed. Changes in the
amplitude of ABR wave I can be more sensitive than threshold
measurements to certain forms of auditory pathology and signal
neuronal malfunction months before histological observation of
neuronal loss [32]. Figure 6C presents the peak-to-peak amplitude
of ABR wave I as a function of tone frequency. For each frequency
and genotype, the data represents the average amplitude of
response to the 60, 70 and 80 dB SPL tone presentations. Wave I
amplitudes are statistically similar between the Fgf23z=z and
Fgf23z={ groups at all frequencies except 32 kHz. At this
frequency, the *20 dB loss detected by threshold measurements
(Fig. 6A) is affecting a significant reduction in amplitude
(pƒ0:01). ABRs were only consistently measured from Fgf23{={
mice at 80 dB SPL for each frequency (due to extremely high
thresholds) and were significantly reduced across the frequency
range (pƒ0:001).
Threshold-adjusted ABR wave I latency values are presented in
Figure 6D. Unlike amplitude, it is customary to present latency
values for tone levels relative to each animal’s hearing threshold
(dB SL) rather than absolute level (dB SPL) [33]. For each
frequency, the data represent the average response latency to tones
presented at 5, 10 and 15 dB SL. Both Fgf23{={ and Fgf23z={
mice have increased wave I latencies, indicating slower neural
signaling. The observed increase is most significant at high
frequencies and more pronounced in the Fgf23{={ genotype.
These results demonstrate profound hearing loss in Fgf23{={
mice, resulting in large part from conductive deficiencies due to
ossicular dysplasia. Fgf23z={ mice demonstrate high-frequency
hearing loss, of mixed conductive and sensorineural origin.
FGF23 Deficiency and Hearing Loss
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evidence for a conductive component to the loss, while the lower
onset frequency of the ABR threshold shifts indicates a sensori-
neural component. ABR wave I latency data also support the
presence of a sensorineural pathology. The near equivalence of
ABR amplitudes in Fgf23z=z and Fgf23z={ mice suggests that
the functional neural populations are of similar size (in agreement
with histology), but the increased latency in Fgf23z={ mice
indicates a retrocochlear phenotype as a result of the mutation
[33]. The increased latency is particularly interesting as no
previous study has identified a heterozygote phenotype.
Discussion
Our findings of significant conductive impairments in
Fgf23{={ mice coupled with a sensorineural component indicate
that the mechanisms of hearing loss due to FGF23 and KL
deficiency are different, albeit possibly overlapping. KL expression
Figure 1. Morphological and histological comparisons of the middle and inner ears. (A) The bullae of Fgf23{={ mice (bottom row) appear
white and cloudy with less structural refinement than both Fgf23z=z (top row) and Fgf23z={ mice (middle row), indicating incomplete ossification.
(B) The auditory ossicles are dysplastic in Fgf23{={ mice. (C) H&E stained, paraffin sections demonstrate increased vascularization of the bony
labyrinth in Fgf23{={ mice (arrowheads). (D) The highly-organized laminar structure of the otic capsule, bordering the spiral ligament, is lost in the
Fgf23{={ genotype. Lines in A and B are orienting lines from the microscope objective.
doi:10.1371/journal.pone.0107681.g001
Figure 2. Morphological comparisons of the otic capsule from (A) Fgf23
z=z, (B) Fgf23
z={ and (C) Fgf23
{={ mice. All genotypes appear
similar but the Fgf23{={ cochlea is slightly smaller and whiter. Black lines are orienting lines from the microscope objective.
doi:10.1371/journal.pone.0107681.g002
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stria vascularis, spiral ligament, outer hair cells, inner hair cells and
spiral ganglion cells [22,23], potentially enabling tissue specific
FGF23 sensitivity. Our immunostaining results demonstrate that
FGF23 is even more widely present throughout the ear than KL,
and suggest that FGF23-KL interaction may be occurring in many
of the inner ear’s critical tissues. Kl
2/2 mice have been shown to
exhibit hearing loss; 14–18 dB threshold shifts have been detected
in ABRs elicited by clicks as well as tones at 4, 8, 16 and 32 kHz in
3 week old 129/SvJ mice [21]. Another study, more directly
comparable to our study due to the common background strain
and similar animal age, observed an *18 dB shift in ABR
thresholds for 8 kHz tones in 6–14 week old C57/Bl6 mice [22].
The authors also analyzed non-threshold adjusted ABR wave I
latency in response to 100 dB SPL tones and found a significant
delay of *0.4 ms in Kl
2/2 mice.
The *50 dB ABR threshold shift we observed across all
frequencies in Fgf23{={ mice is much more severe than the Kl
2/2
phenotypes. Conversely, the observed ABR wave I latency delays
weremore severeinKl
2/2 micethan the *0.2 msdelaysathigher
frequencies in Fgf23{={ mice (we observed no significant delay at
8 kHz). However, because the results from Kl
2/2 mice were non-
threshold adjusted, these metrics are not directly comparable. ABR
latency decreasesas tone intensity (in dB SL) increases;therefore the
latency difference observed in Kl
2/2 mice may have a significant
contribution owing to the *18 dB threshold shift (the significance
of this effect is reduced because tones are well above threshold for
both groups). The threshold-adjusted metric we utilized, where
ABR latencies are measured just above animal threshold, prevents
sensitivity differences from influencing the latency and allows the
result to be more demonstrative of actual differences in the rate of
signal transduction and neural conduction.
Unfortunately, neither of the above studies of Klotho mutations
presented hearing results from Kl
+/2 mice; thus comparison with
the unexpected Fgf23z={ phenotype is not possible. However,
the mixed hearing loss associated with the Fgf23z={ phenotype is
intriguing, particularly the presence of significant threshold-
adjusted latency delays at frequencies below DPOAE threshold
shifts, strongly indicating a neural phenotype. Overall, this
divergence of Fgf23 and Kl phenotypes is made more interesting
by recent research which has suggested a calcineurin-mediated
FGF23 signaling pathway [28], and activation of calcineurin has
previously been shown to contribute to noise induced hearing loss
[34,35].
Our results raise questions concerning the prevalence of hearing
loss among individuals with FGF23 deficiencies. No auditory
phenotype has been reported in FGF23-mediated familial tumoral
calcinosis, which results from a missense mutation in FGF23.
However, diseases with known elevations in serum concentrations
of FGF23 co-present with hearing loss [36]. Our findings
demonstrate that FGF23 deficiency is sufficient to induce
profound sensory impairment in mice. The lack of such an
obvious phenotype in humans suggests important differences
between species, potentially stemming from robust protection
against hypervitaminosis D in humans [21]. Alternatively, a
putative auditory phenotype in humans may be less severe, and
therefore less studied, than the debilitating systemic phenotypes.
Figure 3. Mid-modiolar cochlear sections from Fgf23
z=z (left
column) and Fgf23
z={ mice (right column). (A) Neural populations
and gross anatomical structure appear normal in Fgf23{={ mice. (B)
The stria vascularis (StVas), spiral ligament (SpLig), spiral limbus (SpLim),
tectorial membrane (TM) and Reissner’s membrane (RM) are similar to
Fgf23z=z mice. (C) Inner hair cells (IHC), Outer hair cells (OHC),
supporting cells (SC) and basilar membrane (BM) are morphologically
normal. Sections were embedded in araldite and osmium stained.
doi:10.1371/journal.pone.0107681.g003
Figure 4. FGF23 immunohistochemistry in Fgf23
z=z and Fgf23
{={ mice. (A) Specific staining was observed in the cells of the spiral ligament,
stria vascularis, Organ of Corti, spiral limbus and within the spiral ganglion neuronal cell bodies in Fgf23z=z mice (similar patterns were observed in
Fgf23z={ mice). Inset images are zoomed in views of the boxed regions. (B) No immunoreactivity was observed in Fgf23{={ mice. (C) Similarly, no
staining was observed in negative controls, from Fgf23z=z mice which were processed without the primary antibody.
doi:10.1371/journal.pone.0107681.g004
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media, a clinically important disease that afflicts 75–90% of
Americans at least once before 3 years of age [37,38]. Otitis media
is estimated to cost the national healthcare system more than $4
billion annually [30], and in extreme cases can result in long-term
speech and learning impairments [38]. Currently, genetic risk
factors are poorly understood [29], but the prevalence of pediatric
cases is commonly believed to be related to the ongoing
maturation of the Eustachian tube [39], which undergoes
significant development in the first decade of life. Interestingly,
hyperphosphatemia in Fgf23{={ mice (which precedes other
observed symptoms) first appears at P10 [9]. It is believed that a
FGF23-independent mechanism of phosphate homeostasis must
be functioning prior to this age. Our observations support this
suggestion as structures which are nearly mature by P10 show very
little dysplasia while structures undergoing continued maturation
demonstrate more drastic phenotypes. At P10, the ossicles of
wildtype mice are still surrounded by mesenchyme, indicating
incomplete development, while the remainder of the inner ear
space has begun to clear the mesenchymal tissue [40]. In humans
with reduced FGF23 activity, familial tumoral calcinosis, hyper-
phosphatemia may present as early as 21 months old [41],
Figure 5. 2D and 3D mCT reconstructions of bullae from Fgf23
z=z and Fgf23
{={ mice. Each row contains reconstructions from one ear (top
row: Fgf23z=z, bottom row: Fgf23{={). (A) The otic capsule and bulla show loss of structural refinement and decreased density (arrowheads). (B) In
Fgf23{={ mice the footplate of the stapes demonstrate thickening (arrowheads). (C) The incus and incudomalleal joint are dysplastic (arrowheads)
and the mastoid is under-pneumatized (asterisks). (D) The borders of 3D reconstructed Fgf23z=z ossicles are sharp and well-defined while those of
Fgf23{={ ossicles are blurry due to poor contrast with surroundings, resulting from decreased bone density in the mutant. Fgf23{={ ossicles
demonstrate reduced structural refinement, particularly in the malleus and incus.
doi:10.1371/journal.pone.0107681.g005
Figure 6. Auditory measurements from Fgf mutant mice. (A) ABR and (B) DPOAE thresholds demonstrate profound hearing loss at all
frequencies in Fgf23{={ mice, and moderate hearing loss at high frequencies in Fgf23z={ mice. (C) ABR wave I amplitudes appear slightly depressed
in Fgf23z={ mice but are not statistically differentiable (except at 32 kHz where threshold differences impact magnitude (pƒ0:01)). ABR amplitudes
in Fgf23{={ mice are significantly reduced compared to the other genotypes (pƒ0:001). (D) Threshold adjusted ABR wave I latency measurements
demonstrate significant increases in latency in both Fgf23{={ and Fgf23z={ genotypes when compared to Fgf23z=z littermates (pƒ0:01). Error
bars present standard error of the mean.
doi:10.1371/journal.pone.0107681.g006
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PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e107681indicating that FGF23 is important in phosphate handling when
most episodes of otitis media develop. Given the potential
temporal and mechanistic overlap of initiation of FGF23 activity
and Eustachian tube development, this work suggests a possible
role for FGF23 in the genetic predisposition to otitis media, a link
that warrants further investigation.
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